Status:
UNKNOWN
Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity
Lead Sponsor:
Assiut University
Conditions:
Covid19
Eligibility:
All Genders
18-70 years
Brief Summary
Evaluate effect of DAADs on covid-19 disease.
Detailed Description
If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19
Eligibility Criteria
Inclusion
- HCV patient with or without LC.
- \>18 years old.
- Received DAADs at 2019.
Exclusion
- Combined HCV and HIV infected patients.
- Combined HCV and HBV infected patients.
- \< 18 years old.
- Pregnant or breast-feeding patients.
- Patients with autoimmune disease.
- Patients with multiorgan failure, active cancer, renal insufficiency.
- Patients received immunosuppressive drugs.
- Immune compromised patients.
- Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04729153
Start Date
February 1 2021
End Date
March 1 2022
Last Update
February 3 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.